June 21, 2016
Eli Lilly Japan said on June 20 that it has received approval in Japan for its cancer drug Cyramza (ramucirumab) for the treatment of unresectable, advanced or relapsed non-small cell lung cancer (NSCLC). The approval was given based on the...read more